No quarterly revenue total was found in Quoin Pharmaceuticals, Ltd.'s SEC filings.
Quoin Pharmaceuticals, Ltd. (QNRX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-4.87M
-23.4% vs year-ago quarter
Operating cash flow
$-5.77M
-159.3% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
168.15M
+716.8% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- QNRX (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- Ashburn, VA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671502
- Former names
- Quoin Pharmaceuticals, Ltd. (until Sep 1, 2026); Cellect Biotechnology Ltd. (until Oct 15, 2021); Cellect Biomed Ltd. (until Jul 7, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$4.9M | -$5.4M | -$5.0M | -$4.3M | -$3.9M |
| Operating cash flow | -$5.8M | -$3.1M | -$4.9M | -$5.0M | -$2.2M |
| Total assets | $34.7M | $12.0M | $15.7M | $20.4M | $6.4M |
| Total liabilities | $6.0M | $8.0M | $6.9M | $7.3M | $7.6M |
| Stockholders' equity | $28.7M | $3.9M | $8.8M | $13.1M | -$1.2M |
| Cash and investments | $33.2M | $10.8M | $14.0M | $18.7M | $1.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 10, 2026 | Sep 8, 2026 |
All 583 Quoin Pharmaceuticals, Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.